Comparative Pharmacology
Head-to-head clinical analysis: GADOTERATE MEGLUMINE versus GADOTERIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GADOTERATE MEGLUMINE versus GADOTERIDOL.
GADOTERATE MEGLUMINE vs GADOTERIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadoterate meglumine is a paramagnetic contrast agent that increases the relaxation rate of water protons in tissues, thereby enhancing image contrast in magnetic resonance imaging (MRI). It is a macrocyclic gadolinium-based contrast agent (GBCA) with high thermodynamic stability and kinetic inertness, reducing the risk of gadolinium dissociation.
Gadoteridol is a paramagnetic gadolinium-based contrast agent that increases signal intensity in T1-weighted magnetic resonance imaging by shortening the T1 relaxation time of protons in water molecules. It distributes in the extracellular fluid compartment and does not cross the intact blood-brain barrier, thus enhancing imaging in areas of disrupted barrier or abnormal vascularity.
0.2 mL/kg (0.1 mmol/kg) intravenously as a single bolus injection.
0.2 mL/kg (0.1 mmol/kg) IV bolus, max 20 mL per dose; additional doses up to 0.4 mL/kg may be given within 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life approximately 1.5–2 hours in patients with normal renal function; prolonged in renal impairment (up to 12–34 hours in severe impairment).
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 10-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (99% excreted unchanged in urine within 24 hours); biliary/fecal elimination negligible (<1%).
Renal: >95% unchanged via glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Contrast Agent
Contrast Agent